Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
暂无分享,去创建一个
S. Cummings | M. Nevitt | D. Bauer | M. Hochberg | K. Ensrud | D. Black | D. Thompson | T. Musliner | S. Suryawanshi | D. Black
[1] E. Barrett-Connor,et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.
[2] D. Felsenberg,et al. Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.
[3] S. Cummings,et al. Which Fractures Are Associated with Low Appendicular Bone Mass in Elderly Women , 1991 .
[4] G. Duvel. The study group. , 1980 .
[5] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[6] Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Introduction. , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
[7] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[8] M. Nevitt,et al. Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[10] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[11] M. Chapuy,et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women , 1994, BMJ.
[12] R. Recker,et al. Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis , 1996 .
[13] H. Genant,et al. Chronic intermittent cyclical administration of tiludronate in postmenopausal osteoporosis: report of two multicenter studies in 2136 patients , 1998 .
[14] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[15] N. Breslow,et al. Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .
[16] H. Kang,et al. Vertebral Fracture in Osteoporosis , 1993 .
[17] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[18] N. Breslow,et al. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .